In cohort D of the CHRYSALIS-2 trial, MET immunohistochemistry (IHC) positivity, defined as MET 3+ staining on at least 25% of tumor cells, was observed in 36% of the available pre-treatment tissue biopsies. This evidence concerns the gene MET and neoplasm.